10x Genomics CEO Moves Shares Into Exchange Fund in $1.95M Filing
10x Genomics CEO Serge Saxonov contributed shares worth about $1.95 million to an exchange fund. Here is what the filing shows and what traders should know.
In this article
10x Genomics chief executive Serge Saxonov has reported moving shares worth roughly $1.95 million into an exchange fund, according to a filing reported on 14 November 2026. Insider filings like this one can draw attention from stock traders, but the details matter, because a contribution to an exchange fund is not the same as a plain open-market sale.
Key takeaways
- Saxonov, CEO and a director of 10x Genomics (NASDAQ:TXG), contributed 31,000 Class A shares to an exchange fund.
- The transaction, dated 10 November 2026, was valued at about $1.95 million.
- The shares were valued at $62.90 each to work out how many exchange fund shares he would receive.
- Some data sites label the same Form 4 entry as a "disposal" or "sale", so wording differs between outlets.
What the filing shows
According to Investing.com, the shares went into an exchange fund, a structure that generally lets an investor pool stock in return for fund interests. After the contribution, Saxonov directly holds 1,019,249 shares of 10x Genomics Class A common stock. A Form 4 filed on 13 November showed that post-transaction holding.
The CEO also has indirect exposure through family trusts where he acts as trustee. These include the Andromeda Trust, the Y/S Descendants' Trust and the Y/S Pot Trust.
Some aggregators describe the entry differently. For example, MarketBeat reports it as a sale of 31,000 shares on Tuesday, 10 November, with a 2.95% decrease in his direct position. Traders should read the original SEC filing rather than rely on a headline label.
Why it matters for TXG watchers
Investing.com notes that TXG has risen 266% over the past year, though shares were trading at $58.19, below the exchange fund valuation price. That gap is worth noting, but it does not by itself say anything about the CEO's view of the company.
The company's recent results give extra context. 10x Genomics reported third-quarter 2027 results that beat Wall Street expectations on both earnings and revenue. Revenue came in at $150.66 million against a forecast of $147.93 million.
Insider activity is only one input. Insiders may trade or restructure holdings for tax, diversification or estate-planning reasons. Many such transactions happen under pre-arranged plans, and a single filing rarely signals a change in a company's outlook.
Wider market backdrop
The filing arrived on a weekend, so TXG itself is not trading. Other risk assets were mixed in the latest snapshot. Bitcoin was at 67,091.00, down 1.98% on the day, while Nvidia was at 162.85, down 2.01%. Apple was at 356.27, up 0.39%. In forex, EUR/USD was at 1.10280, down 0.28%.
What to watch next
- Any further Form 4 filings from Saxonov or other 10x Genomics insiders.
- How TXG trades when US markets reopen, relative to the $62.90 valuation figure.
- Management commentary on the company's outlook after the third-quarter beat.
Markets are volatile and this article is for education only, not investment advice.
Frequently asked questions
What did the 10x Genomics CEO do with his shares?
Serge Saxonov contributed 31,000 Class A shares to an exchange fund, in a transaction dated 10 November 2026 and valued at about $1.95 million.
Is this the same as selling shares on the open market?
Not necessarily. Investing.com describes it as a contribution to an exchange fund, while some data sites label the same Form 4 entry a sale or disposal. The SEC filing itself is the best reference.
How many shares does Saxonov directly hold now?
After the transaction, he directly holds 1,019,249 Class A shares, plus indirect holdings through trusts where he serves as trustee.
- 10x genomics CEO Serge Saxonov contributes $1.95M in shares By Investing.com — ca.investing.com
- 10x Genomics CEO Serge Saxonov reports disposal of $1.95 million in common shares - TXG News — rallies.ai
- 10x Genomics (NASDAQ:TXG) Stock: Insider Serge Saxonov Sells 31,000 Shares — marketbeat.com
- 10x genomics CEO Serge Saxonov contributes $1.95M in shares By Investing.com — au.investing.com